Survival of infantile fulminant hepatitis B and treatment with Lamivudine.
Laubscher
B
B
Department of Paediatrics, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. bernard.laubscher@ne.ch
Gehri
M
M
Roulet
M
M
Wirth
S
S
Gerner
P
P
D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy*; D006514:Hepatitis B Surface Antigens / Q000187:drug effects / Q000378:metabolism; D006515:Hepatitis B virus / Q000187:drug effects*; D006801:Humans; D007223:Infant; D019259:Lamivudine / Q000627:therapeutic use*; D017093:Liver Failure / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016019:Survival Analysis; D016896:Treatment Outcome
D006514:Hepatitis B Surface Antigens; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine